financetom
Business
financetom
/
Business
/
U.S. Bancorp's adjusted profit falls as deposit costs hurt interest income
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
U.S. Bancorp's adjusted profit falls as deposit costs hurt interest income
Jul 17, 2024 5:21 AM

July 17 (Reuters) - U.S. Bancorp's ( USB ) adjusted

profit fell about 10% in the second quarter on Wednesday, hurt

by a decline in interest income due to higher deposit costs and

muted loan demand.

Lenders in the U.S. have been offering higher interest

rates to retain deposits in recent months as customers

increasingly seek better returns by placing their money in

higher-yielding alternatives such as money-market funds.

Meanwhile, borrowers have also put off taking loans until

the interest rates normalize, further pressuring consumer-facing

banks.

U.S. Bancorp's ( USB ) net interest income (NII), the difference

between what banks pay customers on deposits and earn as

interest on loans, fell about 9% to $4.05 billion in the quarter

versus a year earlier.

The bank forecast NII to be stable in the current quarter

versus the second quarter levels.

The Minneapolis, Minnesota-based bank also reported a 3.6%

decline in average loans to $374.7 billion.

Net interest margin - a key measure of lending profitability

- contracted to 2.67%, compared with 2.90% in the year-ago

period.

"This quarter, credit metrics continued to perform in line

with expectations, and we believe our reserve levels are

appropriate for future losses. All capital and liquidity ratios

remain strong," CEO Andy Cecere said in a statement.

Net income attributable to the lender, on an adjusted basis,

fell to $1.62 billion or 98 cents per diluted share in the three

months ended June 30. That compares with $1.79 billion or $1.12

per diluted share, a year earlier.

U.S. Bancorp's ( USB ) stock is flat so far this year, and is the

worst performer on a key index tracking rivals. The S&P 500

Banks Index has gained 17.33% over the same period.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Chevron Cabinda Gulf Operations Resume After Release of Oil
Chevron Cabinda Gulf Operations Resume After Release of Oil
Jan 27, 2025
07:03 AM EST, 01/27/2025 (MT Newswires) -- Chevron ( CVX ) said Sunday that its Cabinda Gulf Oil operations in Angola have resumed normal operations after an oil sheen and debris were found nearby along the Atlantic Ocean coastline, Bloomberg reported Sunday. About five barrels of oil were released into the sea in a matter still under investigation, the report...
Pfizer to Pay $59.7 Million to Resolve Biohaven's Alleged Kickback Scheme for Nurtec ODT
Pfizer to Pay $59.7 Million to Resolve Biohaven's Alleged Kickback Scheme for Nurtec ODT
Jan 27, 2025
07:01 AM EST, 01/27/2025 (MT Newswires) -- Pfizer ( PFE ) agreed to pay about $59.7 million to settle allegations that Biohaven Pharmaceutical Holding, before being acquired by Pfizer ( PFE ), defrauded several US health care programs by paying kickbacks to doctors to drive prescriptions of its Nurtec ODT drug for migraine, the US Department of Justice said Friday....
Brazil's JBS buys stake in Mantiqueira to enter egg sector
Brazil's JBS buys stake in Mantiqueira to enter egg sector
Jan 27, 2025
SAO PAULO (Reuters) - Brazilian meatpacker JBS has agreed to buy a stake in Mantiqueira Alimentos, it said on Monday, marking the food giant's entry into the egg sector in a deal that valued Mantiqueira at 1.9 billion reais ($321 million). JBS said in a securities filing it had agreed to purchase shares representing 48.5% of the total capital stock...
Alvotech, Teva Filing for Inflammatory Treatment Candidate Accepted for FDA Review
Alvotech, Teva Filing for Inflammatory Treatment Candidate Accepted for FDA Review
Jan 27, 2025
07:02 AM EST, 01/27/2025 (MT Newswires) -- Alvotech ( ALVO ) and Teva Pharmaceutical (TEVA) said Monday that the US Food and Drug Administration has accepted to review their biologics license applications for AVT05 to treat inflammatory conditions. The review process is expected to be completed in Q4. This comes after the achievement of positive top-line results in April 2024...
Copyright 2023-2026 - www.financetom.com All Rights Reserved